Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. David O’Malley, expert in gynecologic oncology, and members of Agenus’ management team will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday September 21, 2020 at 2:30 p.m. ET.
Dr. David O’Malley will review data of balstilimab as a monotherapy and in combination with zalifrelimab presented at ESMO from the largest clinical trials of IO therapies in refractory cervical cancer, and he will discuss the potential of this proprietary combination.
Members of the Agenus management team will be available to discuss the next steps for balstilimab as monotherapy and in combination with zalifrelimab as well as the progress of other wholly-owned pipeline assets, such as Fc enhanced AGEN1181 and TIGIT monospecific and bispecific molecules.
Investors, media and the general public can access a replay of the conference on Agenus’ website at https://investor.agenusbio.com/events-and-presentations.
Session Details TBA
Smarter Strategies for IoT Deployment
Occupant Wellness in the Indoor Environment